GoAI
Get started
Zhongzhi Pharmaceutical Holdings Limited logo

Zhongzhi Pharmaceutical Holdings Limited

3737.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$0.675

−HK$0.005 · -0.74%

Aug 24, 2:40 PM HKTData delayed

3737.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations are structured across three main divisions: pharmaceutical production, management of its physical retail pharmacy chain, and its online pharmacy platform. The company offers Chinese patent medicines and traditional Chinese decoction pieces, marketed under prominent brands such as Zeus, Liumian, and Caojinghua. In addition to its core pharmaceutical activities, Zhongzhi also produces and sells food products and traditional Chinese herbs, manages properties, and offers detection and testing services. By the end of 2021, the company managed a network of 398 self-owned retail pharmacies. Of these, 361 were approved for medical insurance payments and are situated in Zhongshan, Guangdong Province, operating under the Zeus brand. Established in 1993, the company's headquarters are also located in Zhongshan, PRC. Crystal Talent Investment Group Limited holds a controlling stake in Zhongzhi Pharmaceutical Holdings Limited.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Ying Feng Lai
Listed since
Jul 13, 2015
Employees
2,284

Market position

Day range

Current HK$0.675

52-week range

Current HK$0.675

Open
HK$0.66
Previous close
HK$0.68
Volume
229K
0.59× average
Average volume
387.49K
Average daily volume
Market cap
569.53M HKD
Beta
0.42
Market reference 1
50-day average
HK$0.6704
+0.69% above average
200-day average
HK$0.7173
-5.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
460.99M CNY
EV / EBITDA
8.34×
Earnings yield
3.98%
Free cash flow yield
16.07%

Profitability & efficiency

Return on equity
1.58%
Return on assets
0.94%
Return on invested capital
0.34%

Financial health

Current ratio
1.6×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends67%43%18%-6%Gross margin, FY2021: 60.77%Gross margin, FY2022: 58.45%Gross margin, FY2023: 59.43%Gross margin, FY2024: 58.17%Gross margin, FY2025: 54.12%Operating margin, FY2021: 4.89%Operating margin, FY2022: 5.83%Operating margin, FY2023: 8.28%Operating margin, FY2024: 5.86%Operating margin, FY2025: 0.28%Net margin, FY2021: 2.98%Net margin, FY2022: 5.83%Net margin, FY2023: 7.94%Net margin, FY2024: 4.30%Net margin, FY2025: 1.00%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 60.77%. Gross margin FY2022 58.45%. Gross margin FY2023 59.43%. Gross margin FY2024 58.17%. Gross margin FY2025 54.12%. Operating margin FY2021 4.89%. Operating margin FY2022 5.83%. Operating margin FY2023 8.28%. Operating margin FY2024 5.86%. Operating margin FY2025 0.28%. Net margin FY2021 2.98%. Net margin FY2022 5.83%. Net margin FY2023 7.94%. Net margin FY2024 4.30%. Net margin FY2025 1.00%.

Income trends

Revenue

1.74B CNY-21.55%

Operating income

4.93M CNY-96.20%

Net income

17.29M CNY-81.84%
Income trends across reported periods2.44B CNY1.55B CNY667.89M CNY−216.06M CNYRevenue, FY2021: 1.75B CNYRevenue, FY2022: 1.83B CNYRevenue, FY2023: 2.05B CNYRevenue, FY2024: 2.21B CNYRevenue, FY2025: 1.74B CNYOperating income, FY2021: 85.38M CNYOperating income, FY2022: 106.43M CNYOperating income, FY2023: 169.82M CNYOperating income, FY2024: 129.85M CNYOperating income, FY2025: 4.93M CNYNet income, FY2021: 52.13M CNYNet income, FY2022: 106.39M CNYNet income, FY2023: 162.78M CNYNet income, FY2024: 95.21M CNYNet income, FY2025: 17.29M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.75B CNY. Revenue FY2022 1.83B CNY. Revenue FY2023 2.05B CNY. Revenue FY2024 2.21B CNY. Revenue FY2025 1.74B CNY. Operating income FY2021 85.38M CNY. Operating income FY2022 106.43M CNY. Operating income FY2023 169.82M CNY. Operating income FY2024 129.85M CNY. Operating income FY2025 4.93M CNY. Net income FY2021 52.13M CNY. Net income FY2022 106.39M CNY. Net income FY2023 162.78M CNY. Net income FY2024 95.21M CNY. Net income FY2025 17.29M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue1.74B CNY2.21B CNY2.05B CNY1.83B CNY1.75B CNY
Cost of goods sold797.23M CNY926.38M CNY831.67M CNY758.59M CNY685.15M CNY
Gross profit940.25M CNY1.29B CNY1.22B CNY1.07B CNY1.06B CNY
Research and development41.46M CNY57.01M CNY49.98M CNY46.35M CNY43.83M CNY
Selling, general, and administrative893.86M CNY1.09B CNY994.81M CNY914.57M CNY932.14M CNY
Operating expenses935.32M CNY1.13B CNY1.02B CNY960.92M CNY975.97M CNY
Interest income2.91M CNY5.14M CNY6.99M CNY3.89M CNY4.18M CNY
Interest expense5.24M CNY6.99M CNY7.87M CNY6.56M CNY7.08M CNY
Depreciation and amortization56.96M CNY50.9M CNY102.08M CNY50.37M CNY40.14M CNY
Operating income4.93M CNY129.85M CNY169.82M CNY106.43M CNY85.38M CNY
Net income17.29M CNY95.21M CNY162.78M CNY106.39M CNY52.13M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.01

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.210.120.03-0.06Q2 '21Q4 '21Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual 0.097, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual -0.021, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 25, 2022: actual 0.107, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 23, 2023: actual 0.039, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 24, 2023: actual 0.172, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 23, 2024: actual 0.036, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 23, 2024: actual 0.106, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual 0.015, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates1.25B1.15B1.04B942.92MQ2 '21Q4 '21Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual 1.06B HKD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 1.05B HKD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 25, 2022: actual 990.84M HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 23, 2023: actual 1.12B HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 24, 2023: actual 1.18B HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 23, 2024: actual 1.06B HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 23, 2024: actual 1.17B HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual 1.2B HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.09

2023 complete year+213.0% since 2017

Corporate action history

Dividend

Ex-dividend May 23, 2025

HK$0.05

Annual

Record May 27, 2025 · Payment Jun 13, 2025

Dividend

Ex-dividend May 24, 2024

HK$0.03

Annual

Record May 27, 2024 · Payment Jun 13, 2024

Dividend

Ex-dividend Oct 17, 2023

HK$0.06

Irregular

Record Oct 19, 2023 · Payment Nov 2, 2023

Dividend

Ex-dividend May 23, 2023

HK$0.03

Special

Record May 24, 2023 · Payment Jun 16, 2023

Dividend

Ex-dividend Oct 15, 2020

HK$0.0515

Special

Record Oct 16, 2020 · Payment Nov 2, 2020

Dividend

Ex-dividend May 21, 2020

HK$0.0435

Special

Record May 22, 2020 · Payment Jun 10, 2020

3737.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.1

-4.23%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.2

-2.54%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.40

-5.10%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.34

-5.26%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.35

-2.98%

Continue in GoAI

Research 3737.HK

research.disclaimer